Jiangsu Hengrui Medicine Co., Ltd.
600276
Rangering i aksjer
#544
Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged... Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
Aksjekurs
$6.89
Markedsverdi
$43.94B
Endring (1 dag)
-2.91%
Endring (1 år)
-24.78%
Land
CN
Handel Jiangsu Hengrui Medicine Co., Ltd. (600276)
Kategori
Healthcare
P/B-forhold for Jiangsu Hengrui Medicine Co., Ltd. (600276)
P/B-forhold per October 2026 TTM: 4.71
Ifølge Jiangsu Hengrui Medicine Co., Ltd. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 4.71. Ved slutten av 2024 hadde selskapet et P/B-forhold på 6.39.
P/B-historikk for Jiangsu Hengrui Medicine Co., Ltd. fra 2001 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 4.71 | -25.48% |
| 2025 | 6.32 | -1.09% |
| 2024 | 6.39 | -9.65% |
| 2023 | 7.07 | 9.04% |
| 2022 | 6.49 | -29.84% |
| 2021 | 9.24 | -52.24% |
| 2020 | 19.35 | 24.50% |
| 2019 | 15.55 | 57.24% |
| 2018 | 9.89 | -5.23% |
| 2017 | 10.43 | 45.32% |
| 2016 | 7.18 | -10.85% |
| 2015 | 8.05 | 63.76% |
| 2014 | 4.92 | -13.09% |
| 2013 | 5.66 | 13.80% |
| 2012 | 4.97 | -8.81% |
| 2011 | 5.45 | -40.25% |
| 2010 | 9.12 | 4.84% |
| 2009 | 8.70 | 25.59% |
| 2008 | 6.93 | -35.14% |
| 2007 | 10.68 | 89.97% |
| 2006 | 5.62 | 451.70% |
| 2005 | 1.02 | 5.76% |
| 2004 | 0.96 | -9.87% |
| 2003 | 1.07 | -10.67% |
| 2002 | 1.20 | -6.19% |
| 2001 | 1.28 | 0.00% |
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| 1.3124 | -72.13% |
JP
|
|
| - | - |
CH
|
|
| 5.041 | 7.03% |
IN
|
